Floatz logo

Isocyclophosphamide

Nodal Marginal Zone B-Cell Lymphoma

University of California, DavisSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Nodal Marginal Zone B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
Etoposide
University of California, Davis
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Cyclosporin A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Isocyclophosphamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
B-cell non-Hodgkin lymphomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →